Alto Neuroscience
ANRO
77 hedge funds and large institutions have $67.4M invested in Alto Neuroscience in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 26 reducing their positions, and 12 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3% more call options, than puts
Call options by funds: $82K | Put options by funds: $80K
2% less ownership
Funds ownership: 63.89% → 61.89% (-2%)
4% less funds holding
Funds holding: 80 → 77 (-3)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
31% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 26
44% less capital inflows, than outflows
Capital inflows: $1.93M | Capital outflows: $3.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
+$515K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$314K |
| 3 |
Two Sigma Investments
New York
|
+$238K |
| 4 |
Two Sigma Advisers
New York
|
+$224K |
| 5 |
Renaissance Technologies
New York
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$959K |
| 2 |
BlackRock
New York
|
-$643K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$372K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$254K |
| 5 |
Goldman Sachs
New York
|
-$251K |
ANRO Hedge Fund Activity: Q3 2025 in Review
77 of the 7,653 institutional investors tracked by Wall St. Rank reported a position in Alto Neuroscience (ANRO) for Q3 2025, worth a combined $67.4M — up 77% from $38.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ANRO and 9 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 18 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $515K. The largest seller was UBS Group, cutting an estimated $959K.
- 77 institutional investors held Alto Neuroscience (ANRO) as of Q3 2025, down from 80 in Q2 2025.
- Funds reported $67.4M of Alto Neuroscience stock for Q3 2025, up 77% quarter-over-quarter.
- 9 funds opened new Alto Neuroscience positions in Q3 2025 and 12 closed out, a net change of -3 holders.
- The largest Alto Neuroscience buyer in Q3 2025 was Perceptive Advisors, an estimated $515K added.
- The largest Alto Neuroscience seller in Q3 2025 was UBS Group, an estimated $959K sold.
Based on aggregated 13F filings for Q3 2025.